TS-1 add-on therapy in Japanese patients with triple-negative breast cancer after neoadjuvant or adjuvant chemotherapy: a feasibility study

Purpose We examined the feasibility, efficacy, and safety of TS-1 add-on therapy (TAT) in Japanese patients with triple-negative breast caner (TNBC). Methods TAT (TS-1, 80 mg/m(2)/day, BID, PO), consisting of the 21-day cycles of 14-day consecutive administration followed by 7-day drug holiday, was...

Descripción completa

Detalles Bibliográficos
Autores principales: Inoue, Kenichi, Nagai, Shigenori E., Saito, Tsuyoshi, Sakurai, Takashi, Kimizuka, Kei, Yamada, Hirofumi, Kuroda, Toru, Hata, Satoshi, Yamazaki, Yasuo, Kojima, Masato, Futsuhara, Kazushige
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2019
Materias:
Phase II Studies
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6985043/
https://www.ncbi.nlm.nih.gov/pubmed/31289984
http://dx.doi.org/10.1007/s10637-019-00829-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6985043/
https://www.ncbi.nlm.nih.gov/pubmed/31289984
http://dx.doi.org/10.1007/s10637-019-00829-w

Ejemplares similares